Table 2. Multivariate analysis of OS for patients with mCRPC.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Model without IDC-P status | Model with IDC-P status | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| CFS (mo), ≥ 10 vs. < 10 | 0.33 (0.20–0.56) | 0.000 | 0.25 (0.14–0.45) | 0.000 | 0.28 (0.15–0.50) | 0.000 |
| Gleason score, ≥ 8 vs. < 8 | 2.53 (1.01–6.34) | 0.048 | 1.33 (0.52–3.42) | 0.554 | 1.23 (0.48–3.16) | 0.662 |
| IDC-P status, IDC-P(+) vs. IDC-P(–) | 2.28 (1.35–3.86) | 0.002 | – | – | 1.91 (1.11–3.29) | 0.020 |
| Therapeutic scheme, 1st -line treatment vs. BSC | 0.47(0.27–0.83) | 0.009 | 0.51 (0.28–0.91) | 0.023 | 0.50 (0.28–0.91) | 0.022 |
| ECOG score, ≥ 2 vs. < 2 | 2.56 (1.50–4.35) | 0.001 | 3.65 (2.05–6.48) | 0.000 | 3.68 (2.07–6.56) | 0.000 |
| ALP (IU/L), ≥ 160 vs < 160 | 2.82 (1.66–4.79) | 0.000 | 1.86 (1.03–3.33) | 0.038 | 1.91 (1.05–3.48) | 0.034 |
| LDH (IU/L), ≥ 250 vs < 250 | 2.50 (1.43–4.37) | 0.001 | 1.87 (1.00–3.49) | 0.049 | 1.85 (0.98–3.49) | 0.058 |
| C-index of the model | – | – | 0.756 | – | 0.777 | 0.018* |
*c-index test.
OS = overall survival from CRPC to death; HR = hazard ratio; CI = confidence interval; CFS = CRPC-free survival; IDC-P = intraductal carcinoma of the prostate; ECOG = Eastern Cooperative Oncology Group; BSC = best supportive care; ALP = alkaline phosphatase; LDH = lactate dehydrogenase.